GOLDEN, Colo. – Feb. 22, 2013 – PharmaJet Inc. has entered into a collaboration agreement with CureVac GmbH for delivery of CureVac’s mRNA-based vaccine portfolio including targets in oncology and infectious diseases, using the PharmaJet needle-free jet injector platform.
GOLDEN, Colo. – Feb. 20, 2013 – PharmaJet Inc. has become the first and only needle-free injection company to receive Performance, Quality and Safety (PQS) pre-qualified certification from the World Health Organization (WHO).
GOLDEN, Colo. ‐ Nov. 29, 2012 – PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria® influenza vaccine to be delivered with the PharmaJet Stratis® needle‐free jet injector, as soon as the 2013‐2014 flu season.
GOLDEN, Colo. – June 30, 2011 – Now in its third year, Colorado Companies to Watch attracted over 360 nominees. With nearly 100 companies selected as finalists, PharmaJet prevailed along with 49 others to receive the distinction of...
Golden, Colo. — Dec. 6, 2010 – A Cooperative Research and Development Agreement (CRADA) has been signed between PharmaJet, Inc. and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to utilize the PharmaJet needle-free jet injection delivery technology in conjunction with USAMRIID’s candidate gene-based smallpox vaccine.
Fort Collins, Colo., and Golden, Colo. — Oct. 12, 2010 – Inviragen and PharmaJet announced the award of a five-year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of a needle-free, easy-to-administer dengue vaccine.